Clinical application value of soluble co-stimulatory molecule B7-H1 detection in colorectal cancer
10.3760/cma.j.issn.1009-9158.2018.09.009
- VernacularTitle:可溶性共刺激分子B7-H1检测在结直肠癌辅助诊断中的临床应用价值
- Author:
Minyi XU
1
;
Qiannan LI
;
Lei WANG
Author Information
1. 200235,上海市第八人民医院 上海市第六人民医院徐汇分院检验科
- Keywords:
Colorectal neoplasms;
Antigens,CD274;
Biomarkers;
tumor
- From:
Chinese Journal of Laboratory Medicine
2018;41(9):669-674
- CountryChina
- Language:Chinese
-
Abstract:
Objective To determine the level of soluble B7-H1 (sB7-H1) in serum of patients with colorectal cancer ( CRC) , and to investigate its clinical application value in CRC .Methods 152 cases of CRC, 57 cases of benign colorectal diseases and 59 healthy subjects were enrolled .ELISA was used to determine the sB7-H1 level in serum.The levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 72-4 (CA72-4) were determined by electrochemiluminescence. The level of carbohydrate antigen 50 (CA-50) was determined by chemiluminescence.ROC curve was used to evaluate the diagnostic efficiency of sB 7-H1 alone or combined with other tumor markers in CRC .It also analyzed the correlation between serum sB 7-H1 level and some clinicopathological characteristics including tumor location , depth of invasion , lymph node metastasis status , distant metastasis status and tumor stages.Results (1)The differences of sB7-H1 level among CRC group, colorectal benign disease group and healthy control group ( compared with each other respectively ) were statistically significant ( P<0.001 ) . Levels of CEA, CA19-9, CA72-4 and CA-50 were significantly different between CRC group and benign colorectal disease group ( P<0.05 ) , while there was no significant difference between benign colorectal disease group and healthy control group (P>0.05).(2)The diagnosis ability of sB7-H1, CEA, CA19-9,CA72-4, and CA-50 were determined by the area under curve (AUC), which was 0.730, 0.772, 0.639, 0.663 and 0.635, respectively.The combination of sB7-H1 and CEA showed the best effect , and the AUC reached 0.831.(3)There was no significant correlation between the levels of sB 7-H1 and CEA, or CA19-9, CA72-4, CA-50.(4) Immunohistochemistry result showed that the positive rate of CRC group was 52％, while that of benign disease group was 6.3％.The difference of the positive rate between two groups was statistically significant (P<0.01).And there was a significant correlation between the positive rate of sB 7-H1 level in serum and tumor tissues of CRC patients ( P<0.05 ) .( 5 ) The serum sB7-H1 level in CRC patients was related to lymph node metastasis status (P<0.05).But there was no relationship between sB7-H1 level and other clinicopathological characteristics ( including tumor location , depth of invasion , distant metastasis status and tumor stage ) (P>0.05).Conclusion Serum sB7-H1 has a high clinical application value and could serve as a new tumor marker in CRC .
